549 related articles for article (PubMed ID: 3733147)
1. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
[TBL] [Abstract][Full Text] [Related]
2. C56 formation in the reaction mixture of isolated complement components through the classical complement pathway.
Kitamura H; Tsuboi M; Nagaki K
Int Arch Allergy Appl Immunol; 1985; 78(1):101-7. PubMed ID: 4030125
[TBL] [Abstract][Full Text] [Related]
3. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
4. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
5. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
6. C3-independent immune haemolysis: mechanism of membrane attack complex formation.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Sep; 59(1):147-51. PubMed ID: 3759127
[TBL] [Abstract][Full Text] [Related]
7. Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
Tamura N; Baba AS
Immunology; 1976 Jul; 31(1):151-8. PubMed ID: 1027719
[TBL] [Abstract][Full Text] [Related]
8. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of immune haemolysis by a serum factor found in C3-deficient subjects.
Kitamura H; Tsuboi M
Immunology; 1989 Feb; 66(2):264-9. PubMed ID: 2925225
[TBL] [Abstract][Full Text] [Related]
10. Lytic activity of C5-9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity.
Yamamoto KI
J Immunol; 1977 Oct; 119(4):1482-5. PubMed ID: 894048
[TBL] [Abstract][Full Text] [Related]
11. C3-independent immune haemolysis: haemolysis of EAC14oxy2 cells by C5-C9 without participation of C3.
Kitamura H; Matsumoto M; Nagaki K
Immunology; 1984 Nov; 53(3):575-82. PubMed ID: 6237987
[TBL] [Abstract][Full Text] [Related]
12. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
13. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
14. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
15. Terminal complement components play a role in the expression of C5a.
Gresham HD; Renfer L; Hammer CH; Frank MM
J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
[TBL] [Abstract][Full Text] [Related]
16. Deviated lysis: Transfer of complement lytic activity to unsensitized cells II. Generation of the activity by inulin and by antigen antibody complexes.
Rother U; Hänsch G; Rother K
Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):442-54. PubMed ID: 785847
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
[TBL] [Abstract][Full Text] [Related]
18. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
19. The release of C5a in complement-activated serum does not require C6.
Biesecker G; Wagner JL; Hugli TE
J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
Strunk RC; Giclas PC
J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
[No Abstract] [Full Text] [Related]
[Next] [New Search]
